← Back to Search

Vinca alkaloids

Oxaliplatin + Navelbine for Lung Cancer

Phase 2

Waitlist Available

Led By Thomas A Marsland, MD

Research Sponsored by Integrated Community Oncology Network

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Locally advanced or metastatic non-small cell lung cancer that has recurred, progressed, or failed to respond to previous systemic chemotherapy

Good performance status (ECOG 0, 1, or 2)

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

Study Summary

This trial will test the safety and effectiveness of combining two drugs, oxaliplatin and Navelbine, to treat patients with advanced non-small cell lung cancer who have already tried other treatments.

Who is the study for?

This trial is for people with advanced non-small cell lung cancer (NSCLC) that has come back or didn't respond to initial chemotherapy. Participants should have measurable disease, a good performance status, and must not have been treated with Oxaliplatin or Navelbine before. Those with symptomatic brain metastases cannot join.Check my eligibility

What is being tested?

The study is testing the effectiveness of combining two drugs, Oxaliplatin and Navelbine, as a second-line treatment for NSCLC. This combination hasn't been studied before but aims to see if it can shrink tumors in patients who've had chemo previously.See study design

What are the potential side effects?

Potential side effects may include nerve damage (neuropathy), fatigue, nausea, vomiting, diarrhea from Oxaliplatin; and bone marrow suppression leading to low blood counts, weakness and hair loss from Navelbine.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My lung cancer has spread or worsened despite chemotherapy.

Select...

I can take care of myself and perform daily activities.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Efficacy

Secondary outcome measures

Duration of response

Survival

Time to progression

+1 more

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

Integrated Community Oncology NetworkLead Sponsor

SanofiIndustry Sponsor

2,163 Previous Clinical Trials

3,512,440 Total Patients Enrolled

Thomas A Marsland, MDPrincipal InvestigatorIntegrated Community Oncology Network

Media Library

Navelbine (Vinca alkaloids) Clinical Trial Eligibility Overview. Trial Name: NCT00238849 — Phase 2

Non-Small Cell Lung Cancer Research Study Groups:

Non-Small Cell Lung Cancer Clinical Trial 2023: Navelbine Highlights & Side Effects. Trial Name: NCT00238849 — Phase 2

Navelbine (Vinca alkaloids) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00238849 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is the age requirement for this research study open to individuals over 50?

"This medical trial is open to adults within the 18-65 age range."

Answered by AI

Who qualifies to participate in this investigation?

"This clinical study aims to recruit 40 participants aged 18 and over with lung cancer. To be eligible, individuals must have advanced or metastatic non-small cell lung cancer that has relapsed after systemic chemotherapy as well as measurable disease and a good ECOG performance status (0, 1, or 2)."

Answered by AI

Does this therapeutic option pose a threat to patient safety?

"Due to this being a Phase 2 trial and lacking efficacy data, our team has determined that the safety of this treatment falls at score of 2 on a 1-3 scale."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Phase II Study of Oxaliplatin and Navelbine for Second-Line Treatment of Advanced NSCLC.

2024. "Phase II Study of Oxaliplatin and Navelbine for Second-Line Treatment of Advanced NSCLC.". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00238849.

All > Metastatic Lung Cancer > Lung Cancer